Overview

Evaluation of the Effect of Benzonatate on QT Intervals Following Single Dose Administration of Benzonatate to Healthy Volunteers

Status:
Completed

Trial end date:
2014-07-01

Target enrollment:

Participant gender:

Summary

The primary objective of this study is to determine the effects of benzonatate (200 mg and 800 mg) on the QT interval following single dose oral administration at each time point post-dose.

Phase:

Phase 1

Details

Lead Sponsor:

Pfizer

Treatments:

Benzonatate
Fluoroquinolones
Moxifloxacin
Norgestimate, ethinyl estradiol drug combination